Alnylam will receive $310M up front, additional near-term fees incl. development milestones over the next few years, regulatory & sales milestones for ~$2.8B along with royalties on net sales of zilebesiran outside the US as well as an equal share of profits & losses in the US
Alnylam to get an equal profit share in the US & will lead a joint clinical development plan for 1st indication with Roche’s participation incl. cardiovascular outcomes trial with development costs shared 40% by Alnylam & 60% by Roche
Roche will get an exclusive right to commercialize zilebesiran outside the US & may lead development for additional indications in the future. The collaboration will combine Alnylam’s leadership in RNAi therapeutics with Roche’s global commercial reach to develop & launch innovative therapies globally for sev. cardiovascular diseases
Ref: Businesswire | Image: Alnylam
Related News:- Alnylam Reports Updated Interim Results from the P-I Study of ALN-APP for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
